TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Surrozen ( (SRZN) ).
On November 6, 2025, Surrozen appointed Andrew Maleki as Chief Financial Officer, effective November 12, 2025. Maleki, with a strong background in corporate development and program leadership in the biotech industry, is expected to enhance Surrozen’s strategic capabilities and support its long-term growth. The company also reported its third-quarter financial results, highlighting a net loss of $71.6 million, increased research and development expenses, and a focus on advancing its ophthalmology pipeline. Surrozen continues to progress its lead candidates, SZN-8141 and SZN-8143, in retinal diseases, aiming to submit an IND application for SZN-8141 in 2026.
The most recent analyst rating on (SRZN) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Surrozen stock, see the SRZN Stock Forecast page.
Spark’s Take on SRZN Stock
According to Spark, TipRanks’ AI Analyst, SRZN is a Neutral.
Surrozen’s overall stock score reflects significant financial challenges, including consistent losses and a weak balance sheet. While recent corporate events, such as the private placement, provide a positive outlook for liquidity, the technical indicators and valuation suggest caution. The company needs to address its financial instability and improve cash flow management to enhance its stock performance.
To see Spark’s full report on SRZN stock, click here.
More about Surrozen
Surrozen is a biotechnology company focused on pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a particular emphasis on severe eye diseases. The company leverages its expertise in Wnt biology and antibody technologies to develop novel treatments for ophthalmic conditions.
Average Trading Volume: 26,987
Technical Sentiment Signal: Buy
Current Market Cap: $106.4M
For a thorough assessment of SRZN stock, go to TipRanks’ Stock Analysis page.